These therapies have improved patient responses in many tumor types that previously had few effective treatments, such as RAF inhibitors for metastatic melanoma [1] and epidermal growth factor receptor (EGFR) inhibitors for EGFR mutant non-small cell lung cancer (NSCLC) [2]. The gene discussed is EGFR; the disease is neoplasm.